America's addiction: pharma and the opioid epidemic

3 October 2016
oxycontin-abuse-big

Opioids are powerful painkillers and undoubtedly have a role to play in managing severe short-term and chronic pain, but it is their side effects which so often prove problematic. The sense of euphoria and wellbeing induced by opiates is recognized as highly addictive and naturally makes opiate-based drugs open to abuse.

Legitimate patients all too often resort to taking more than prescribed by their doctor or than is required to manage their pain, in order to chase the high, becoming physically and/or physiologically dependant in the process.

"In 2007, Purdue and three of its executives pleaded guilty in a federal court to charges of misleading regulators, doctors and patients over the risk of addiction and potential for abuse by misbranding OxyContin."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical